Slides
Page 1
2165 SL 901 / R Corporate Presentation August 2026 HARROWⓇ Your patients . Our purpose .
Page 2
2 Corporate Presentation | August 2026 Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the “Company” or “Harrow”). Some of these risks and uncertainties include, but are not limited to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration related to compliance and quality plans at our outsourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. The Company’s compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners. This presentation refers to non-GAAP financial measures, specifically adjusted EBITDA. A reconciliation and/or further description of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company’s Letters to Stockholders, available on its website. All content included in this presentation is intended for investors and the investment community and is not intended as marketing material or for use by healthcare professionals and their patients.
Page 3
3 Corporate Presentation | August 2026 | Anti-VEGF Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes Payer Types: Disease Origins: Product Categories: Largest U.S. portfolio of prescription ophthalmic products, broadly covering the ophthalmic anatomy Key revenue drivers are best- in-class products with large market opportunities Scalable commercial platform; innovative approach to market access and distribution Delivery Types: Injectable | Topical Drops | Nasal Spray Buy & Bill | Branded | Generic Over-the-Counter | Compounded Anterior | Posterior | Ocular Surface Commercial | Government | Cash • Access and affordability are foundational Harrow commitments • Access for All programs ensure eligible patients can receive Harrow products for as low as $0, or a maximum of $59 • Harrow commercial infrastructure scales, allowing future acquisitions to “plug-in” and begin to generate revenue G-MELT | Sedation 2028 | Dry Eye Disease | PF Corticosteroid (Inj.) | Anti-VEGF | Ocular Anesthesia 2027 Drug Candidate TM Diversified provider of ophthalmic disease management solutions in North America Harrow. We Are Ophthalmic Pharma.
Page 4
4 Corporate Presentation | August 2026 Harrow. We Are Ophthalmic Pharma.
Page 5
5 Corporate Presentation | August 2026 Ocular Anesthesia 44% Unit demand growth Q2 ’26 vs Q1 ‘26 • Highest unit demand quarter since launch • 34% YoY unit demand growth • 224 ordering accounts, +32% YoY; 62 new in Q2 > all of H1 2025 • ~25% net pricing increase (7/1/26); multi-unit packaging launched Injectable Corticosteroid (preservative-free) 39% Unit demand growth Q2 ’26 vs Q1 ‘26 • Strongest quarter in product history – unit demand up 162% YoY • Momentum: May 2026, strongest month, ↑151% versus May 2025 • 54% of Q2 unit volume from ocular surgery accounts • 3X surgical salesforce (during H1 2026) • Phase 3 data and label expansion on track Upcoming Growth Catalysts Acquisition Expands DED leadership; immediate strategic growth driver; attractive price • BYOOVIZ launched 7/1/2026; expanding growing retina franchise • VERKAZIA relaunched into VKC; improving Rx volumes • IOPIDINE J-Code effective July 1; strong reception at ASRS for high- volume IVIs (GA and Eylea HD injections); YAG and SLT IOP control • MELT programs on track; launch expected in H2 2028 Dry Eye Disease 21% TRx growth Q2 ’26 vs Q1 ‘26 • Outpaced branded DED market growth during Q2 (21% vs. 14%) • 40% revenue growth, Q2 ‘26 vs Q1 ‘26 • 15% prescriber growth Q2 ’26 vs Q1 ’26 • 4% NRx growth Q2 ’26 vs Q1 ’26 • 14.6% market share as of end of June ’26 • 2X salesforce & new coverage expected to drive NRx & TRx growth Key revenue drivers in growth mode; revenue catalysts through 2029 Investment Highlights See References, slide 34
Page 6
6 Corporate Presentation | August 2026 Durable Growth: Launches & Pipeline Launching at least one product every year through 2029 – within Harrow’s existing cost structure and commercial footprint Q3 2026 2H 2026 2027 2028 2028 H2 2028 / H1 2029 Clobetasol Topical Steroid Dry Eye Disease Nasal Spray Anti-VEGF Biosimilar G-MELT Ketamine + Midazolam ODT YOCHIL Midazolam ODT Series H-NO8 Triamcinolone Acetonide PFS COMMERCIAL LA UNCHES PIPELI NE 1 2 3 4 5 6
Page 7
7 Corporate Presentation | August 2026 Financials & Outlook 2Q26 | Results and Outlook Key Financial Metrics and Revenue Conversion
Page 8
8 Corporate Presentation | August 2026 Key Financial Metrics Five years of consistent revenue and EBITDA expansion FIVE-YEAR TRACK RECORD C O N S O L I D A T E D R E V E N U E $ in millions 41% 5-Yr CAGR $72.5M $88.6M $130.2M $199.6M $272.3M $357.5M $0M $100M $200M $300M $400M 2021 2022 2023 2024 2025 2026E A D J U S T E D E B I T D A $ in millions 62% 5-Yr CAGR $11.4M $13.0M $28.1M $40.3M $61.9M $90.0M $0M $25M $50M $75M $100M 2021 2022 2023 2024 2025 2026E Q2 2026 Key MetricsQ2 2026 Key Metrics REVENUE $70.7M ADJ. EBITDA $(1.2)M P R O D U C T R E V E N U E VEVYE $29.4M IHEEZO $15.6M Specialty + TRIESENCE $11.0M Compounded $14.6M $83.9M Cash & Equivalents (as of June 30, 2026) TYRVAYA to be funded from cash on hand — no dilution, no new debt FY ’26 Revenue $350M – $365M Midpoint ~$357.5M FY ‘26 EBITDA $80M – $100M Midpoint ~$90M Reaffirming 2026 Financial Outlook See References, slide 34 (Midpoint) (Midpoint)
Page 9
9 Corporate Presentation | August 2026 H1-H2 2026: Converting Demand to Revenue Q2's +60% sequential revenue growth came with five key levers still switched off — all five are now live in H2 2026 H1 2026 · BUILDING DEMAND +60% sequential revenue growth $44.2M → $70.7M Q1 to Q2 2026 revenue Q2 2026 DEMAND — ALL-TIME HIGHS IHEEZO 65,477 units +44% vs Q1 2026 VEVYE $29.4M +40% vs Q1 2026 TRIESENCE 14,529 units +39% vs Q1 2026 H2 2026 · CONVERTING TO REVENUE +39–45% Avg. growth needed per quarter $114.9M → $235–250M H1 to H2 revenue target FY2026 GUIDANCE — REITERATED $350–365M revenue $80–100M adjusted EBITDA $250M (goal) In quarterly revenue, by the end of 2027 WHAT WAS MISSING IN H1 NOW LIVE FOR H2 IHEEZO Pricing: pass-through lost April 1 IHEEZO Pricing: net price up ~25%, effective July 1 Field Force: hired, not yet productive Field Force: VEVYE 2x, surgical 3x, added to all other teams Channel Inventory: destocking drag on revenue Channel Inventory: normalized, revenue tracks demand VEVYE Economics: rules changed late April, pre -deductible VEVYE Economics: rules live, Rx growth + new coverage (8/1) New Products: BYOOVIZ commercial launch July 1 New Products: BYOOVIZ and VERKAZIA live, TYRVAYA 2H
Page 10
10 Corporate Presentation | August 2026 Dry Eye Disease VEVYE | TYRVAYA | Harrow’s Dry Eye Portfolio Market Leadership, Growth and Differentiation
Page 11
11 Corporate Presentation | August 2026 Building the Leading Dry Eye Portfolio VEVYE remains our first -line therapy for chronic dry eye disease. By adding TYRVAYA, along with other ocular surface treatments in the Harrow portfolio, like FRESHKOTE ® and FLAREX ®, we can now provide prescribers with a more complete approach to treating DED using multiple, fundamentally different mechanisms of action ONE COMMERCIAL ENGINE. BROADER PHYSICIAN CHOICE. FASTER GROWTH FOR BOTH BRANDS. EXPANDS OUR ADDRESSABLE MARKET TYRVAYA allows us to reach drop-fatigued patients, ~45M US contact lens wearers, and those needing rapid, predictable tear production LEVERAGES EXISTING INFRASTRUCTURE Built on Harrow's commercial, market access & reimbursement platform — plus Viatris' experienced DED sales force ATTRACTIVE DEAL TERMS; INCLUDES GLOBAL RIGHTS $30M upfront, up to $70M in one-time net-sales milestone payments that are structured to increase expected transaction ROI FIRST-LINE ANCHOR THERAPY Best-in-class cyclosporine; rapid, durable efficacy Foundation of Harrow's Dry Eye Disease portfolio + COMPLEMENTARY DED PRESCRIPTION PRODUCT Neural-pathway nasal spray — no eye drop required Complements VEVYE with a differentiated mechanism To be funded from cash on hand — no dilution to stockholders and no incremental interest costs
Page 12
12 Corporate Presentation | August 2026 VEVYE — Best-in-Class for DED ~22x More cyclosporine delivered into the cornea vs. Restasis Preclinical ex-vivo corneal penetration study data Rapid Onset Fastest-working immunomodulator for DED Durable Effect Significant staining improvement by Day 15, sustained to 56 weeks Well-Tolerated 99.8% of patients experience no or mild instillation pain IP Protection Orange Book–listed patents expiring in 2039 M A R K E T O P P O R T U N I T Y DED Patient Funnel ~93% of diagnosed U.S. patients are not on Rx 38M+ Americans with dry eye symptoms 16.4M Diagnosed U.S. adults (6.8%) 9.0M Moderate-to-severe disease 1.2M On Rx therapy ~20% annual Rx growth DED Rx volumes growing ~20% annually over last 2 years The first and only water-free cyclosporine for the signs and symptoms of dry eye disease See References, slide 34
Page 13
13 Corporate Presentation | August 2026 VEVYE Q2 2026 Key Metrics ~4% NRx Growth Q2 '26 vs Q1 '26 ~21% TRx Growth Q2 ’26 vs Q1 ‘26 +15% Prescriber Growth Q2 '26 vs Q1 '26 14.6% Market Share As of end of June ‘26 Quarterly Revenue U.S. net revenue | Q2 ‘25 → Q2 ‘26 $18.6M $22.6M $25.9M $20.9M $29.4M $M $5M $10M $15M $20M $25M $30M $35M Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q2 Highlights • Outpaced branded Dry Eye Disease market growth: VEVYE TRx grew 21% QoQ vs. 14% branded DED category TRx growth (IQVIA Xponent) • Increased TRx market share to 14.6% in Q2 • Improved VEVYE economics, with meaningfully lower co-pay card utilization, higher ASP, and normalized channel inventories • Continued physician adoption, with prescribers increasing 15% sequentially • Expanded commercial coverage, with top-three commercial PBM (Aug. 1) • Doubled commercial team, expected to support continued prescription growth throughout the second half of 2026 See References, slide 34 +40% Revenue Growth Q2 '26 vs Q1 '26
Page 14
14 Corporate Presentation | August 2026 TYRVAYA — Differentiated Treatment The only FDA-approved nasal spray for DED — stimulating natural tear production through a different pathway than drops THE MECHANISM • Selective nicotinic receptor agonist — activates the trigeminal pathway to stimulate tears • No drop, no drug placed on the eye — works through the nose, not the ocular surface • Tear production increases on average ~5 minutes after the first dose THE CLINICAL EVIDENCE • Proven in ONSET -1, ONSET-2 & MYSTIC — 1,000+ patients studied • ~50% of patients showed a significant tear increase at 4 weeks vs. 14 –28% on vehicle • First & only FDA -approved nasal spray for dry eye disease (approved Oct. 2021) WHO IT'S BUILT FOR • Broadens Harrow's addressable DED market, complementing VEVYE with a differentiated, non-drop treatment option • Patients who struggle with or resist eye drops • No contact lens removal required (~45M U.S. contact lens wearers) • Patients with aqueous -deficient DED, drop fatigue, or poor adherence to topical therapy • 2 bottles = 30-day supply • 60 sprays per bottle (4.2 mL each) • 0.03 mg varenicline solution TWELVE ORANGE BOOK LISTED PATENTS WITH EXPIRY IN 2035 ZERO Contraindications · Ocular AEs · Label Warnings >$30M 2027 revenue Expected TYRVAYA contribution (once closed)
Page 15
15 Corporate Presentation | August 2026 01 Anti-Inflammatory Chronic inflammatory DED — the seminal long-term therapy. H VEVYE Cequa∆ Restasis∆ Xiidra∆ VEVYE VALUE • Only water-free cyclosporine (0.1%) • SFA vehicle → greater corneal delivery • Relief by Day 15 vs. months for Restasis • No dysgeusia (taste change) – a known side effect of Xiidra • Signs & symptoms; lowest patient discomfort data 02 Basal Tear Production Aqueous-deficient DED — drop-free tear stimulation. H Tyrvaya Tryptyr∆ TYRVAYA VALUE • Nasal spray — no drop/drug on the eye • Stimulates natural tear production • Only option not requiring lens removal (~45M U.S. wearers) • Multi-year record + broad coverage 03 Tear Film Stabilization Evaporative DED / MGD — lubricates and stabilizes the tear film. H FreshKote Miebo∆ OTC drops F RESHKO TE VALUE • Triple-action polymer — all three tear layers • Uniquely high oncotic pressure • Draws fluid from epithelium; restores tear film integrity • Fraction of branded cost 04 Steroids Acute inflammatory flares — rapid, short -term symptom control. H Flarex Eysuvis∆ Loteprednol F LAREX VALUE • Acetate base provides prednisolone- level penetration • Strong potency for moderate inflammation • Safer fluorometholone IOP profile • Far less steroid-response pressure rise • Cash-pay access option available H Harrow-owned ∆ Not a Harrow -owned product or trade name CHRONIC EPISODIC EPISODIC EPISODIC Full Spectrum Leadership Harrow fields products engineered to win – on efficacy, patient experience, and economics For illustrative purposes only. See References, slide 34 for trademark attribution and comparative -claim disclosures.
Page 16
16 Corporate Presentation | August 2026 Ocular Anesthesia IHEEZO | In-Office Ocular Surface Anesthesia Market Opportunity, Clinical Profile, and Access
Page 17
17 Corporate Presentation | August 2026 IHEEZO Overview • First-in-class: only branded ocular anesthetic approved in the U.S. in nearly 14 years1 • Large TAM: >14M annual U.S. ocular procedures require surface anesthesia2 • Reimbursement unlocked: permanent J-Code (J2403) in the in-office setting3 • IP runway: two Orange Book patents, latest expiring 20394 • Clinical advantage: rapid onset, lower pain vs. tetracaine, no supplemental dosing required, inactive ingredient hydroxyethyl cellulose, typically used in eye lubricants/tears Sterile, single-patient-use, physician-administered, ophthalmic gel preparation for ocular surface anesthesia, approved by the FDA in September 2022 IHEEZO clinical studies demonstrated 5: ~1-1.5 Min. IHEEZO worked rapidly IHEEZO had lower pain scores vs tetracaine Sufficient anesthesia to perform the surgical procedure ~22 Min. No patient required supplemental dosing See References, slide 34
Page 18
18 Corporate Presentation | August 2026 IHEEZO Total Addressable Market ~14M+ All eight procedure categories are IHEEZO -applicable | CPT codes shown with each procedure Estimated Annual U.S. In -Office Procedures | Standard of Care Requires Ocular Surface Anesthesia 0.2M 0.3M 0.3M 0.5M 0.7M 1.0M 1.5M 10.0M Estimated Annual U.S. Procedure Volume (millions) Intravitreal Injections 67028 Laser Procedures 65855 / 66761 / 67210 Gonioscopy (Procedural) 92020 Foreign Body Removal 65222 / 65205 Other In-Office Various Corneal Procedures 65435 / 0402T Punctal Occlusion 68761 Glaucoma Implant 66183-66185 See References, slide 34
Page 19
19 Corporate Presentation | August 2026 IHEEZO Q2 2026 Key Metrics +44% Unit Demand Growth Q2 ‘26 vs Q1 ‘26 +32% Total Ordering Accounts 224 total · 62 first -time in Q2 85.5% Re-Order Rate Trailing 12 months ~25% Increase in Net Pricing Effective Q3 2026 Quarterly Customer Unit Demand FY 2024: 128,585 units → FY 2025: 201,215 units → 56% growth +34% YoY Entering Peak Season 38,940 48,765 50,565 62,945 45,509 65,477 0 20,000 40,000 60,000 80,000 Q1 Q2 Q3 Q4 2025 2026 Q2 Highlights Strongest Quarter in Product History • All-time high in unit demand New Account Momentum at Record Pace • 224 total ordering accounts (+32% YoY) • 62 new accounts in Q2 alone exceeded all of H1 2025 Net Pricing Increase + New Packaging Effective July 1 • ~25% improvement in net price per unit • Robust supply of new 5-unit packaging Interim Retina Clinical Data – ASRS July 2026 • IHEEZO patients more pain-free at 24hrs vs. subconjunctival lidocaine • QUELL study (larger IND trial) topline expected Q4 2026 In-Office Channel Gaining Momentum Record unit demand, ordering accounts and re -order rate | Net pricing up ~25% effective Q3 2026 See References, slide 34
Page 20
20 Corporate Presentation | August 2026 Injectables TRIESENCE | Ophthalmic Injectable Portfolio Market Opportunity and Commercial Update
Page 21
21 Corporate Presentation | August 2026 TRIESENCE Overview Injectable suspension (triamcinolone acetonide 40 mg/mL) with separate reimbursement in every traditional care setting1 Regulatory Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use Supply 5-year supply agreement with CMO; next-generation product candidate in development (H2 2028 / H1 2029 launch) Reimbursement Product-specific J-Code (J-3300); CMS pass-through status since April 2025 IP Protection Orange Book–listed patents through 2029; next generation launch expected pre-expiry Commercial Expansion into Ocular Inflammation 7M+ Annual potential U.S. use cases in ocular inflammation Consistent favorable post-op outcomes reported by physicians Removes reliance on patient eye drop compliance Reimbursed in every care setting — ASC, HOPD, and office 96% Covered Lives ~$38 Patient Out-of-Pocket See References, slide 34
Page 22
22 Corporate Presentation | August 2026 TRIESENCE Q2 2026 Key Metrics +39% Unit volume growth Q2 ‘26 vs Q1 ‘26 54% Volume from Ocular Surgery Accounts Q2 ‘26 +69 Net new accounts QoQ 805 total accounts – highest since launch 7Qs Consecutive growth Since re-launch Quarterly unit demand Unit demand per quarter | Q1 ‘25 → Q2 ‘26 +162% YoY 4,444 5,615 9,650 10,37710,492 14,529 0 2500 5000 7500 10000 12500 15000 17500 Q1 Q2 Q3 Q4 2025 2026 Q 2 H i g h l i g h t s Strongest Quarter in Product History • May 2026 was the strongest single month ever up 151% vs. May 2025 Account Adoption Reaching Scale • Majority of new accounts driven from expansion into ocular inflammation Surgical Sales Force Tripled in Q2 • New reps joined mid-quarter – full productivity expected in H2 2026 Phase 3 Data and Label Expansion on Track • Clinical trial for ocular inflammation & pain post-cataract surgery underway • Topline data expected early 2027 – potential to expand TAM Next-Generation Product Candidate as the Long-Term Catalyst • Next-generation product candidate expected to carry its own NDA • Provides better patient experience, greater pricing flexibility + materially improved net profitability vs. current product See References, slide 34
Page 23
23 Corporate Presentation | August 2026 Anti-VEGFs BYOOVIZ | OPUVIZ | Ophthalmic Biosimilars Market Opportunity and Differentiated Approach
Page 24
24 Corporate Presentation | August 2026 Best-in-Class Anti-VEGF Biosimilars Two FDA-approved ophthalmic biosimilars acquired from Samsung Bioepis — addressing the largest market in ophthalmology Strategic fit — leveraging existing commercial infrastructure with clinical synergy alongside IHEEZO, TRIESENCE and IOPIDINE REFERENCED DRUG INDICATIONS STATUS U.S. LAUNCH First FDA-approved LUCENTIS® referenced biosimilar FDA-approved EYLEA® referenced biosimilar ● Neovascular (Wet) Age-Related Macular Degeneration ● Macular Edema following Retinal Vein Occlusion (RVO) ● Myopic Choroidal Neovascularization (mCNV) ● Neovascular (Wet) Age-Related Macular Degeneration ● Macular Edema following RVO ● Diabetic Macular Edema (DME) & Diabetic Retinopathy Interchangeability Status Interchangeability Status Launched July 1, 2026 U.S. Launch Planned: 2027 See References, slide 34
Page 25
25 Corporate Presentation | August 2026 Anti-VEGF Market A defined market opportunity met with a differentiated, relationship -led commercial strategy U.S. Anti-VEGF Market ~8.5M units annually | >$4.2B Medicare Part B spend 17.6% 11.8% 18.9% 21.9% 29.8% ALL OTHER¹ AFLIBERCEPT BIOSIMILARS² VABYSMO EYLEA (2 MG) AVASTIN (COMPOUNDED) 2025 U.S. Anti-VEGF Injection Share (by Product) Harrow's Differentiated Launch Strategy Account-Level Retina Relationships • Years of trusted service to retina practices position us to engage at the account & patient level, not on price • Physicians prioritize supplier reliability, service, and consistency — attributes Harrow has demonstrated at scale Integrated Continuum of Care • IHEEZO (anesthesia), BYOOVIZ (anti-VEGF), and TRIESENCE (inflammation) support the full procedure-through-recovery journey • An integrated portfolio single-product competitors can’t match Commercial Flexibility at Launch • Plan to offer extended payment terms to creditworthy customers • A meaningful lever in buy-and-bill economics — designed to accelerate adoption from day one See References, slide 34
Page 26
26 Corporate Presentation | August 2026 Specialty and Access+ VERKAZIA | NATACYN | Specialty Portfolio Steroids, NSAIDs and Anti -Inflammatories
Page 27
27 Corporate Presentation | August 2026 Specialty and Access+ Q2 2026 HIGHLIGHTS • IOPIDINE J-Code effective July 1, improving reimbursement and supporting commercial adoption • VERKAZIA relaunch underway, with initiatives focused on expanding access, improving reimbursement, ensuring reliable supply, and increasing physician awareness • NATACYN clinical study advancing, with patient enrollment underway and topline data expected in Q4 2026 • Access+ commercial organization expanded, supporting the broadest cash- pay ophthalmic portfolio STEROIDS — NSAIDs — ANTI- INFLAMMATORIES ANTIHISTAMINE — ANTIBIOTIC — STEROID COMBINATION VERNAL KERATO - CONJUNCTIVITIS (VKC) Only FDA-approved product for VKC ANTI-FUNGAL Only FDA-approved anti-fungal INTRAOCULAR PRESSURE CONTROL COMPOUNDED FORMULATIONS ImprimisRx — broadest cash - pay portfolio Eleven branded ophthalmic products + ImprimisRx compounded formulations
Page 28
28 Corporate Presentation | August 2026 IOPIDINE® Enabled by Reimbursement Only FDA-approved therapy to prevent procedural IOP spikes C L I N I C A L E V I D E N C E Indication Only FDA-approved product to prevent IOP spikes after certain in-office laser procedures ~91% risk reduction Severe IOP spikes drop from ~23% untreated to ~2% with IOPIDINE Risks if unmanaged Eye pain, blurred vision, and potential optic nerve damage in vulnerable patients R E I M B U R S E M E N T I N F L E C T I O N EFFECTIVE JULY 1, 2026 Historically underutilized — no in-office reimbursement pathway, leaving IOPIDINE a cost center for physicians paid out of a capitated fee. The J-code now allows physicians to bill and be reimbursed at WAC +3% to 6% at launch, moving to ASP +6%. MARKET OPPORTUNITY 1.5M+ Annual U.S. laser procedures ~91% Relative risk reduction J-Code Effective July 1, 2026 DRIVERS OF ADOPTION Aging population: Growing procedure volumes; earlier intervention is standard of care Prevention economics: Reduces follow-up visits and complication costs Unique indication: No FDA-approved alternative with an established J-code Strong anecdotal reception: Feedback at recent ASRS meeting was very positive; physicians want to use on- label, appreciate avoidable practice costs; J-code aligns incentives with evidence-based practice See References, slide 34
Page 29
29 Corporate Presentation | August 2026 The VERKAZIA® Opportunity VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight -threatening cases), which primarily affects children, but can reach into adulthood THE DISEASE SPECTRUM MILD VKC Underdiagnosed; itching, redness with few Rx options beyond antihistamines; large patient population SEVERE VKC Sight-threatening; corneal damage risk without adequate treatment STEROID RISKS Glaucoma/cataract risks make long-term steroid use untenable in children WHY IT MATTERS — THE CLINICAL GAP ~61% of VKC patients are inadequately controlled on antihistamines alone1 0 FDA-approved steroid-sparing therapy existed before VERKAZIA THE GAP: Antihistamines treat symptoms. Steroids carry long -term risk. No steroid-sparing immunomodulator has addressed the full VKC population — leaving a large unmet need across both mild and severe disease THE VERKAZIA OPPORTUNITY • Only steroid-sparing immunomodulator approved for VKC • Clinically proven: significant corneal improvement, symptom reduction & less steroid rescue vs. control • Guideline-supported: 2023 consensus recommends early CsA use for long- term management • Mild (new-to-Rx) and severe (steroid-dependent) patients represent a large, underpenetrated opportunity Chronic inflammation can progress to corneal damage and vision -threatening complications See References, slide 34
Page 30
30 Corporate Presentation | August 2026 The NATACYN® Opportunity Blepharitis is not a single infection — it is a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens THE ETIOLOGIC TRIAD BACTERIA Staphylococcus — lipases, toxins, biofilms5 DEMODEX MITES Mechanical damage, bacterial vectors6 FUNGI Candida / Malassezia — under-recognized and persistent7 WHY IT MATTERS — THE CLINICAL GAP ~50% of patients fail when only bacteria or mites are treated8,9 ~79% of chronic cases show fungal elements; a largely untreated base10 THE GAP: Antibiotics treat bacteria; Xdemvy ® treats mites; There is no standard therapy that addresses the fungal component — leaving post- Xdemvy non-responders symptomatic. THE NATACYN OPPORTUNITY • Only FDA-approved ophthalmic antifungal • Triple-therapy is biologically rational: antibacterial + antiparasitic + antifungal addresses all three pathogens • Entry point: Xdemvy® non-responders — a large, underpenetrated refractory population • Investigator-initiated study: first patients enrolled in Q2 2026; topline data expected Q4 2026 FUNGUS ON THE MITE AND EYELIDS Demodex Mite: 300 – 400 micrometers (µm) 2 Fungus (Hyphae/Yeast): 2 – 10 micrometer (µm)3 Bacteria: 0.5 – 2 micrometers (µm) 4 BACTERIAL COLONIES DEMODEX MITE See References, slide 34
Page 31
31 Corporate Presentation | August 2026 MELT Programs G-MELT | YOCHIL | Sedation Pipeline Non-IV, Opioid-Free Sedation Programs in Development
Page 32
32 Corporate Presentation | August 2026 G-MELT: IV & Opioid-Free Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA - approved molecules in a novel form WHAT MAKES G-MELT DIFFERENT Zydis® sublingual technology Dissolves in seconds under the tongue. Exclusive license from Catalent; Zydis® has supported 35+ FDA-approved products over nearly three decades Superior PK profile Rapid absorption through sublingual mucosa results in rapid, systemic circulation and better bioavailability profile than via GI tract absorption Pharmacologic synergy Midazolam offsets the negative effects of ketamine — delivering effective sedation without IV lines or opioids M A R K E T O P P O R T U N I T Y 5M+ Annual U.S. cataract surgeries — G-MELT’s initial target market 100M+ Potential short -duration procedures in several large markets P A T H T O L A U N C H Regulatory Milestones Remaining ancillary studies NDA Submission Potential FDA Approval See References, slide 34 P A T H T O L A U N C H Regulatory Milestones Remaining ancillary studies Initiated Pre-NDA meeting — granted by FDA Granted; early Q4 2026 – dossier preparation in parallel NDA Submission H1 2027 Potential Launch H2 2028 Potential FDA Approval H1 2028
Page 33
33 Corporate Presentation | August 2026 YOCHIL: Pediatric Oral Midazolam ODT Oral dissolving tablet delivering midazolam for sedation, anxiolysis, and amnesia prior to diagnostic, therapeutic, or endoscopic procedures in pediatric patients WHAT MAKES YOCHIL DIFFERENT De-risked clinical pathway Extensive clinical dataset generated through the G-MELT (MELT-300) program, supporting a streamlined 505(b)(2) regulatory pathway Validated proprietary ODT platform Built on the same proprietary Zydis® sublingual platform as G-MELT, dissolving under the tongue in seconds Addresses an unmet pediatric need Oral midazolam, currently available only as a syrup, can be challenging for children to tolerate, and a fast-dissolving tablet has the potential to improve both the patient and provider experience B R O A D C O M M E R C I A L O P P O R T U N I T Y 7M+ Annual Pediatric Procedures Potential broad label across multiple pediatric procedural settings, supporting a significant commercial opportunity See References, slide 34 P A T H T O L A U N C H Key Regulatory Milestones End-of-Phase 2 FDA meeting Completed Protocol refinement Incorporating FDA feedback PK bridging study to midazolam syrup Under consideration Potential Launch 2028 NDA Submission 2027
Page 34
34 Corporate Presentation | August 2026 References Sources and footnotes for figures cited throughout this presentation Data sources Market, prescription, and procedure data are drawn from IQVIA (including Xponent), PhilRx, Vestrum Health, Market Scope, Definitive Healthcare, the AAO IRIS Registry, CMS HCPCS/CPT databases and Medicare Part B payment limit files, company annual reports, Review of Optometry, and Harrow internal data and data on file. U.S. dry eye disease patient funnel: Farrand et al., Am J Ophthalmol 2017;182:90-98 (16.4M diagnosed U.S. adults, 6.8% of adult population); Prevent Blindness (2019) (moderate-to-severe population); and published U.S. analyses of dry eye symptom prevalence and prescription treatment rates. Regulatory and clinical sources Regulatory information is drawn from FDA Drugs@FDA, the FDA Orange Book, and FDA-approved product labeling. Clinical and conference sources include Ophthalmology (2024), Frontiers in Medicine (2026), the OIS Dry Eye Conference (March 2021), and data presented at ASRS 2026. Certain figures are internal estimates derived from these datasets and from internal development plans. Non-GAAP financial measures Adjusted EBITDA is defined as net income (loss), excluding the effects of stock-based compensation, interest, taxes, depreciation, amortization and other non-recurring items. Compound annual growth rates are calculated for the period 2020 through 2025. Product comparisons Product comparisons are for illustrative purposes only. No head-to- head clinical trials have been conducted comparing one product versus another. Comparative statements reflect FDA-approved labeling and publicly available information and are not intended as promotional or clinical claims. Trademarks All third-party trademarks, trade names, and product names are the property of their respective owners and are used for identification purposes only. Their use does not imply any affiliation with, or endorsement by, Harrow. Pending transactions and forward-looking information The acquisition of TYRVAYA remains subject to closing conditions. Statements regarding anticipated launches, revenue contribution, regulatory milestones, and market opportunity are forward-looking and are subject to the risks and uncertainties described in Harrow's filings with the Securities and Exchange Commission.